Top-line generic product revenue of $7.8 million; TWIN Phase 3 trials are fully enrolled and remain on track to report results in 4Q19. NESS ZIONA, Israel, Aug.
Sol-Gel Technologies Reports Second Quarter 2019 Financial Results and Corporate Update - GlobeNewswire
Read More
No comments:
Post a Comment